Why the study?
AF is highly prevalent among patients receiving maintenance hemodialysis and patients with STEMI, but its association with clinical outcomes in hemodialysis patients admitted with STEMI required investigation.
Does atrial fibrillation increase in-hospital and 1-year mortality in hemodialysis patients admitted with STEMI?
Does atrial fibrillation increase in-hospital and 1-year mortality in hemodialysis patients admitted with STEMI?
Atrial fibrillation is highly prevalent and associated with increased short- and long-term mortality in hemodialysis patients presenting with STEMI.
AF identifies higher-risk hemodialysis STEMI patients; leaves open whether anticoagulation modifies outcomes.
Rationale & Objective: Atrial fibrillation (AF) is highly prevalent among patients receiving maintenance hemodialysis (HD) and patients with ST elevation myocardial infarction (STEMI). We investigated the association of AF with in-hospital mortality, 1-year mortality, and 1-year readmission for acute myocardial infarction (AMI) in HD patients admitted with STEMI. Study Design: Retrospective cohort study based on a large administrative database. Setting & Participants: 138,939 patients admitted with STEMI from 2003-2018, of whom 1,185 (8.5%)receiving HD, followed from the date of admission until death, migration, or 1 year after discharge. Exposures: [ICD-9-CM] 410.x) as the primary discharge diagnosis, maintenance HD (ICD-9-CM 39.95; 54.98; V560; V563.1; V563.2), and AF (ICD-9-CM 427.31). Outcomes: In-hospital all-cause mortality (primary outcome), 1-year all-cause mortality, and 1-year readmission for AMI (secondary outcomes). Analytical Approach: Multivariable logistic regression and multivariable Cox regression. Results: One hundred and ninety-five out of 1,185 (16.5%) patients had AF at admission or developed AF during hospitalization. After adjusting for possible confounders, AF versus sinus rhythm was associated with higher in-hospital mortality (odds ratio [OR] = 1.57; 95% confidence interval [CI], 1.11-2.22). AF was associated with higher 1-year mortality (hazard ratio [HR] = 1.45; 95% CI, 1.18-1.76), whereas it was not associated with higher 1-year readmission for AMI (HR = 1.05; 95% CI, 0.72-1.53). Less than 20% of patients with AF discharged alive were prescribed oral anticoagulant therapy. In this subgroup, oral anticoagulant therapy was associated with lower 1-year mortality (HR = 0.46; 95% CI, 0.24-0.89). Limitations: Potential bias due to incorrect or incomplete coding, retrospective design, incidence of thromboembolic events after discharge, and cause of 1-year mortality unknown. Conclusions: AF is highly prevalent and associated with adverse short- and long-term outcomes in HD patients admitted with STEMI.
No takes yet. Share an insight, caveat, or question.
Genovesi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: